Patients
ascites, poorly-controlled diabetes, cirrhosis, heart or pulmonary diseases, pain, vertigo, Liver Frailty, dizziness, HCC, AKI, Frailty, hepatic decompensation, acute kidney injury
ASCITES, CIRRHOSIS, MALIGNANCIES, HEPATOCELLULAR CARCINOMA, PORTAL HYPERTENSION
All patients diagnosed with frail stable Child-Pugh A or B cirrhosis aged between 18 and 75 years were eligible for inclusion in this study. The diagnosis of cirrhosis was based on a combination of clinical, biochemical, and radiographic data or histology if available. Frailty was diagnosed based on the Liver Frailty Index (LFI) ≥ 4.5. The exclusion criteria were as followed: current or recent (within the previous 6 months) clinical signs or symptoms of hepatic decompensation (grade 2 or 3 ascites, portal hypertension (PHT)-related gastrointestinal (GI) bleeding, hepatic encephalopathy (HE), or acute kidney injury (AKI)), history of hospitalization within the previous 6 months, presence of hepatocellular carcinoma (HCC) or other malignancies, received BCAA supplementation within 1 year, severe chronic heart or pulmonary diseases, chronic hemodialysis, pregnancy, active alcohol intake, poorly-controlled diabetes (hemoglobin A1C > 7%), patients who cannot follow commands or answer the questionnaire, patients who experienced recent joint pain, vertigo, dizziness, or functional disabilities during the inclusion period, and refusal to participate in this study.